164 results on '"Haselkorn T"'
Search Results
2. 49P Epidemiologic study of XL-MTM and clinical expression in the liver (EXCEL): study design of an observational, patient-centric study.
3. P305 ANCILLARY TREATMENT NEEDS OF PATIENTS RECEIVING ORAL IMMUNOTHERAPY FOR FOOD ALLERGY IN CLINICAL PRACTICE
4. PCR-mediated recombination in amplification products derived from polyploid cotton
5. Real-World Maintenance Strategies and Persistence with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
6. P227 ASTHMA EXACERBATION REDUCTION IN ADULTS WITH HIGH/LOW AIRWAY REVERSIBILITY FOLLOWING OMALIZUMAB TREATMENT: RESULTS FROM PROSPERO
7. P226 EFFECT OF OMALIZUMAB IN ASTHMA PATIENTS BY NUMBER OF ASTHMA-RELATED AND ALLERGIC COMORBIDITIES IN PROSPERO
8. P305 REPORTED PRACTICE LOGISTICS FOR IMPLEMENTATION OF SUBCUTANEOUS IMMUNOTHERAPY VERSUS FOOD ORAL IMMUNOTHERAPY AMONG US-BASED ALLERGISTS/IMMUNOLOGISTS
9. Effect of Reversibility and Eosinophils on Lung Function Improvement with Omalizumab Treatment: Pooled Analyses in Patients with Moderate or Severe Allergic Asthma
10. EFFECTS OF OMALIZUMAB ON MARKERS OF TYPE 2 INFLAMMATION: RESULTS FROM THE EXTRA STUDY
11. EFFECT OF OMALIZUMAB ON SEASONAL EXACERBATIONS IN ADOLESCENTS AND ADULTS WITH MODERATE-TO-SEVERE ALLERGIC ASTHMA
12. INCREASED INCIDENCE AND PREVALENCE OF PEANUT ALLERGY IN CHILDREN AND ADOLESCENTS IN THE UNITED STATES
13. PREDICTORS OF A FUTURE SEVERE ASTHMA EXACERBATION AFTER A DECADE FOLLOW-UP: RESULTS FROM TENOR II
14. ATTITUDES AMONG U.S.-BASED ALLERGISTS AND IMMUNOLOGISTS ABOUT IMMUNOTHERAPY, PEANUT EXPOSURE AND TREATMENT
15. CONGENITAL MYOPATHIES (CNM)
16. Long-term outcomes from a pediatric subgroup of TENOR I: 10 years follow up
17. Reduction of Exacerbations by Baseline Indicators of Asthma Severity in Children Receiving Omalizumab
18. P230 Long-term assessment of the burden of atopic sensitization in patients with severe/difficult-to-treat asthma
19. P208 Contribution of obesity to disease burden in children with severe or difficult-to-treat asthma
20. A multicenter, retrospective medical record review of patients with X-Linked Myotubular myopathy (XLMTM): the RECENSUS study
21. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma
22. O018 Asthma exacerbations and triggers in children with severe/difficult-to-treat asthma: Impact on quality of life
23. O020 Asthma exacerbations and lung function decline in children during a 52-week controlled trial of omalizumab
24. FRI0200 Incident Malignancies Following Initiation of Rituximab for Rheumatoid Arthritis: Analysis from The Sunstone Registry
25. P.256 - A multicenter, retrospective medical record review of patients with X-Linked Myotubular myopathy (XLMTM): the RECENSUS study
26. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960
27. The isolation of nucleic acids from fixed, paraffin-embedded tissues-which methods are useful when?
28. Characterization and Predictors of Asthma Exacerbations in Patients on Steps 4, 5 And 6 Therapy in the TENOR Cohort
29. Economic Burden of Impairment in Children with Severe or Difficult-to-Treat Asthma
30. How Do Rates of Asthma Exacerbations Compare in Pediatric and Adult Patients in TENOR?.
31. Asthma Control and Risk of Future Asthma Exacerbations: Evaluation of the Impairment Domain of the NHLBI Guidelines in the TENOR Cohort
32. Association Between Recent and Future Asthma Exacerbations in Pediatric Patients With Severe or Difficult-to-Treat Asthma
33. Relationship Between Asthma Control and Activity Limitation: Insights From the REACT Study
34. PAA1 RELATIONSHIP BETWEEN MEASURES OF ASTHMA CONTROL AND COMBINATION THERAPY TREATMENT REGIMENS IN SEVERE OR DIFFICULT-TO-TREAT ASTHMA
35. Allergy, Serum IgE, and Lung Function in Children and Adolescents With Severe or Difficult-to-Treat Asthma
36. Skin testing and IgE levels in patients with severe or difficult-to-treat asthma
37. Racial disparities in asthma-related health outcomes in severe or difficult-to-treat asthma.
38. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study.
39. Descriptive epidemiology of thyroid cancer in Los Angeles County, 1972-1995.
40. Real-World Evaluation of Asthma Control and Treatment (REACT): Findings from a National Web-Based Survey
41. Demographic and Clinical Characteristics of Children and Adolescents with Severe or Difficult-to-Treat Asthma
42. Evaluation of the National Heart, Lung, and Blood Institute guidelines impairment domain for classifying asthma control and predicting asthma exacerbations.
43. Economic burden of impairment in children with severe or difficult-to-treat asthma.
44. 36P Liver involvement in myotubular and centronuclear myopathy: review of one year's data collected by the MTM & CNM Patient Registry.
45. CONGENITAL MYOPATHIES (CNM): P.139Mortality and respiratory support in X-Linked myotubular myopathy: The RECENSUS Study, an international, multicenter, retrospective medical record review.
46. A healthcare claims analysis to identify and characterize patients with suspected X-Linked Myotubular Myopathy (XLMTM) in the Brazilian Healthcare System.
47. Real-world analysis of healthcare resource utilization by patients with X-linked myotubular myopathy (XLMTM) in the United States.
48. Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global Registry.
49. Impact of body mass index on omalizumab response in adults with moderate-to-severe allergic asthma.
50. Omalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of EXTRA.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.